Patients who benefited most were those who still had relatively good control of their blood sugar levels and only a moderate need for insulin injections when the trial began. With the experimental drug, teplizumab, they were able to maintain their level of insulin production for the full two years — longer than with most other […]
A drug in clinical trials has been shown to preserve insulin-producing pancreatic beta cells in nearly half of subjects newly diagnosed with type 1 diabetes. Results of the phase 2 trials are published in the journal Diabetes.
This retrospective cohort study determined the effect of colesevelam HCL initiation and A1C level in patients with type 2 diabetes regardless of other anti-diabetic medication use.
In yet another boost to several large drugmakers, the FDA has agreed with European regulators there is no existing evidence to confirm recent concerns that a widely used group of diabetes drugs called GLP-1 inhibitors is linked to pancreatic cancer, an FDA spokeswoman says.
Mice that were fed the drug, called metformin lived about 5 percent longer than those that were not fed the drug. The treated mice lived 160 weeks, while those not taking the drug lived about 150weeks.
Statin therapy in individuals who had a low risk of cardiovascular disease was not cost effective when the therapy’s potential to increase the risk of diabetes was taken into account, according to an analysis by researchers at the Centers for Disease Control and Prevention.
Regulators in Europe have concluded that there is little evidence that widely used drugs to treat Type 2 diabetes could cause pancreatic inflammation or pancreatic cancer, a finding that might reassure patients while also removing a potential sales threat for Merck and some other drug companies.
A new pooled analysis shows DPP-4 inhibitors have a greater safety and tolerability profile when compared to other antihyperglycemic agents.
Targeted products include Zostrix Diabetic Foot Pain Relief Cream, DiabeRex, marketed as “the New Diabetes Miracle,” and Glytain, billed as “the all-natural way to support normal blood sugar levels”.
A British drug company is looking to medical marijuana- or at least a derivative of it-to help treat a variety of different diseases, including type 2 diabetes.
In 2007 physicians cited evidence from several studies indicating that Avandia increased the risk of heart attack and cardiac death.
A new class of cholesterol-fighting drugs could be coming to patients in the not-so-distant future, and experts say they could be a real game-changer in Americans’ battle to lower artery-clogging LDL, or “bad,” cholesterol.
While there is still no cure for diabetes, there is a growing number of therapies available to those battling the disease-and even more are in the works, according to experts who spoke at a recent symposium.
In 2 phase 3 trials examining the concept of triweekly dosing with the long-acting insulin degludec (Tresiba, Novo Nordisk) in patients with type 2 diabetes, the recipients had inferior glucose control and an increased risk for hypoglycemia.
A new study says that people newly diagnosed with Type 2 can do better if they are immediately started on a three-drug combo. Does this make sense to you? Is it good science or bad medicine?
Insulin sensitizers–drugs that increase sensitivity to insulin such as Avandia and Actos–could help lessen the risk of peripheral arterial disease (PAD) for those with type 2 diabetes, according to a new study.
Non-adherence to diabetes medication is more likely to occur among young adults, women, those who use retail pharmacies and those who are new to diabetes therapies
A study of the drug—the prescription pain reliever salsalate—also found it reduced inflammation associated with type 2 diabetes. But it produced unwelcome side effects that could limit its potential as a diabetes treatment.
A new, first-in-its-class drug for type 2 diabetes has just been approved by the Food and Drug Administration. Invokana works by blocking re-absorption of glucose by the kidneys and stimulating urination, which removes glucose from the bloodstream.
Today, we bring you more from the American Diabetes Association’s 73rd Scientific Sessions in Chicago, an update on the most interesting new drugs, and some stand-out research.